All Stories

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

Mar 10, 2025 - 17:02
 0
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.
Read More

Tags:

Previous Article

Dexcom receives FDA warning letter over CGM manufacturing issues

Next Article

Novo Nordisk shares fall on latest trial results for new obesity drug

Related Posts

Chutes & Ladders—Sage CMO steps down amid pipeline struggles

Chutes & Ladders—Sage CMO steps down amid pipeline stru...

Mar 7, 2025  0

Amgen ends Ideaya cancer combination trial after partner unveils rival molecule

Amgen ends Ideaya cancer combination trial after partne...

Feb 13, 2025  0

How To Check Transmission Fluid: A Complete Guide

Mar 8, 2025  0